Reported Earlier, HUTCHMED’s Oral Syk Inhibitor Sovleplenib Gets US FDA Orphan Drug Designation For Autoimmune Hemolytic Anemia, Its Second After Primary ITP, Eligible For 7 Years Of US Market Exclusivity Upon Approval
Benzinga Newsdesk 1 day ago
News
Eligible for development incentives including 7 years of US market exclusivity upon regulatory approval Marks the second US FDA Orphan Drug Designation for sovleplenib, following its recent designation for primary ITP
- Eligible for development incentives including 7 years of US market exclusivity upon regulatory approval
- Marks the second US FDA Orphan Drug Designation for sovleplenib, following its recent designation for primary ITP